CervoMed Inc.

Contributing Author

Recent Articles by CervoMed Inc.

Mar-19	CervoMed Announces New Data at the AD/PD 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology CRVO GlobeNewswire
Mar-17	CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates CRVO +5.10% GlobeNewswire
Mar-12	CervoMed Announces Presentations at Upcoming AD/PD 2026 Scientific Conference CRVO GlobeNewswire
Mar-05	CervoMed to Participate in Upcoming Investor Conferences CRVO GlobeNewswire
Mar-04	CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies CRVO GlobeNewswire
Feb-18	CervoMed's neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis CRVO +8.59% GlobeNewswire
Dec-04	CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies CRVO +9.42% GlobeNewswire
Dec-02	CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) CRVO -10.85% GlobeNewswire
Nov-24	CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference CRVO GlobeNewswire
Nov-10	CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates CRVO GlobeNewswire
Nov-04	CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies CRVO GlobeNewswire
Oct-28	CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley CRVO GlobeNewswire
Oct-20	CervoMed to Present at the Emerging Growth Conference CRVO +6.07% GlobeNewswire
Oct-08	CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies CRVO GlobeNewswire
Oct-07	CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer CRVO GlobeNewswire
Oct-02	CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference CRVO GlobeNewswire
Sep-17	CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference CRVO GlobeNewswire
Sep-03	CervoMed to Participate in Upcoming Investor Conferences CRVO +5.89% GlobeNewswire
Aug-11	CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates CRVO GlobeNewswire
Aug-05	CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference CRVO +7.72% GlobeNewswire
Jul-28	CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration CRVO GlobeNewswire
Jul-24	CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025 CRVO +11.55% CRVO GlobeNewswire
Jul-08	CervoMed Announces Late-Breaking Presentations at Alzheimer's Association International Congress 2025 CRVO +7.41% GlobeNewswire
Jun-10	CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization CRVO GlobeNewswire
May-12	CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates CRVO +7.18% GlobeNewswire
May-07	CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference CRVO -5.01% GlobeNewswire

CervoMed Inc.

Recent Articles by CervoMed Inc.

Upgrade your Finviz experience